The marked reduction in metastatic capacity and cancer cell proliferation following ALYREF [157], THOC1 [21,153] and LUZP4 [19] depletion further suggests that there may be therapeutic benefit in targeting TREX. This evidence concerns the gene LUZP4 and cancer.